4 completed, 2 terminated, 2 withdrawn, 1 unknown. 3 Phase 1, 3 Phase 2, 3 Phase 3, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 3 | 3 | Completed 1, Unknown 1, Withdrawn 1 |
| Early Phase 1 | 1 | Completed 1 |
| Not applicable | 1 | Terminated 1 |
Follow Humoral Hypercalcemia Of Malignancy: new trials by email Literature Review of Humoral Hypercalcemia Of Malignancy trials Research Report on Humoral Hypercalcemia Of Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM JMT103 - Hypercalcemia of Malignancy | Phase 1 / Phase 2 | Terminated | Shanghai JMT-Bio Inc. | 4 | 2020-04-22 | 2026-09-18 |
| One Week Comparison Study of PTH and PTHrP Infusions Parathyroid Hormone-related Protein (1-36), parathyroid hormone (1-34), PTH (1-34) and PTHrP (1-36) - Osteoporosis, Hypercalcemia of Malignancy | Phase 1 | Withdrawn | University of Pittsburgh | 2015-01-01 | 2014-12-05 | |
| Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium denosumab - Breast Cancer, Hypercalcemia of Malignancy | Phase 2 | Completed | Amgen | 33 | 2009-11-16 | 2018-10-17 |
| One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study PTHrP (1-36) - Osteoporosis, Humoral Hypercalcemia of Malignancy | Early Phase 1 | Completed | University of Pittsburgh | 14 | 2008-01-01 | 2016-02-11 |
| S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone ibandronate, zoledronate, quality-of-life assessment - Breast Cancer, Hypercalcemia of Malignancy | Phase 3 | Withdrawn | SWOG Cancer Research Network | 2006-05-01 | 2013-11-13 | |
| Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone zoledronic acid, quality-of-life assessment - Breast Cancer, Hypercalcemia of Malignancy | Not applicable | Terminated | University of Leeds | 1500 | 2006-03-01 | 2022-05-27 |
| Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer ibandronate sodium, zoledronic acid, Zolendronic Acid - Breast Cancer, Hypercalcemia of Malignancy | Phase 3 | Unknown | Wales Cancer Trials Unit | 1404 | 2006-01-01 | 2013-03-13 |
| Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases monoclonal antibody CAL, zoledronic acid - Breast Cancer, Hypercalcemia of Malignancy | Phase 1 / Phase 2 | Completed | Chugai Pharmaceutical | 2002-11-01 | 2013-05-15 | |
| Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone zoledronic acid, quality-of-life assessment - Hypercalcemia of Malignancy, Lung Cancer | Phase 3 | Completed | Novartis | 600 | 1998-08-01 | 2013-02-21 |
Neoplasm Metastasis (6) · Breast Neoplasms (5) · Pain (4) · Breast Neoplasms, Male (2) · Carcinoma, Non-Small-Cell Lung (2) · Endocrine System Diseases (2) · Hyperparathyroidism (2) · Lung Neoplasms (2) · Musculoskeletal Diseases (2) · Neoplasms (2) · Osteoporosis (2) · Bone Diseases, Endocrine (1) · Colonic Neoplasms (1) · Endocrine Gland Neoplasms (1)
Neoplasms by Site (6) · Neoplastic Processes (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Breast Diseases (5) · Neoplasms (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Neurologic Manifestations (4) · Signs and Symptoms (4) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Parathyroid Diseases (3) · Bone Diseases (2) · Bone Diseases, Metabolic (2)
Zoledronic Acid (5) · Ibandronic Acid (2) · parathyroid hormone-related peptide (1-36) (2) · Antibodies, Monoclonal (1) · Denosumab (1) · Parathyroid Hormone (1) · Parathyroid Hormone-Related Protein (1)
University of Pittsburgh (2) · Amgen (1) · Chugai Pharmaceutical (1) · Novartis (1) · SWOG Cancer Research Network (1) · Shanghai JMT-Bio Inc. (1) · University of Leeds (1) · Wales Cancer Trials Unit (1)
United States (5) · United Kingdom (2) · Canada (1) · China (1) · France (1) · Italy (1) · Poland (1)
Dawn Hershman, MD (1) · Jin LI, PHD (1) · Kathy S. Albain, MD (1) · Mara J Horwitz, MD (1) · Mara J. Horwitz, MD (1) · Paula Silverman, MD (1) · Peter J. Barrett Lee, MD (1) · Robert E. Coleman, MD, FRCP (1) · Robert Knight, MD (1) · Saul E. Rivkin, MD (1)
PMID 21544866, PMID 23990665, PMID 24332514, PMID 28274254
R01DK073039 (1), U10CA037429 (1)